Leadership Team

We have brought together the domains of pharmaceutical leadership, clinical patient experience, user-centered design, and scalable technical implementation to build a company that is focused on providing the best solution to patients and pharmaceutical companies.

David Schmidt

President & CEO

David Schmidt is President & CEO of TIESRx™ and is responsible for executing corporate and business strategies. His vision is to establish TIESRx™ as the new standard of care in resolving known failure points ultimately driving patient outcomes and driving value to all stakeholders.

David has held a variety of leadership positions over 25 years within the pharma/biotech sectors inclusive of sales, training, operations, marketing as well as market access across federal, state, veterans administration and commercial payers. His area of expertise is within the Orphan Disease space, specifically Limited Distribution Drugs for products requiring high touch services as well as market access and pull-through sales creation and execution.

Email: david.schmidt@tiesrx.com

Glenn Goldenberg

CTO & SVP, Engineering

Glenn Goldenberg is the Chief Technology Officer and Senior Vice President of Engineering at TIESRx™. He is responsible for the architecture and development of the TIESRx™ software platform. Glenn leverages his experience leading teams through all aspects of the software development lifecycle to create a secure and scalable healthcare solution.

Glenn brings over 18 years of experience building enterprise software in early stage through Fortune 100 environments to the TIESRx™ team. He most recently served as Director of Engineering at Videology Group where he developed innovative solutions in the emerging targeted television advertising space. Previously, Glenn worked as a Principal Engineer creating large scale master data and identity management solutions in the government and healthcare sectors at Initiate Systems and IBM. Glenn also gained extensive experience building custom software for large enterprise clients as a Software Consultant with Trilogy Software. Glenn graduated magna cum laude from Cornell University with a Bachelor of Science in Mechanical Engineering.

Email: glenn.goldenberg@tiesrx.com

Jaclyn Rychel

EVP, Business Development

Jaclyn Rychel is Executive Vice President, Business Development of TIESRx™ and is responsible for identifying opportunities and partners for the purpose of customizing TIESRx™ to markets across a variety of therapeutic areas.

Jaclyn has 20+ years in the Biotechnology / Pharmaceutical Industry spanning four companies with experience in the specialties of Oncology, Cardiology, and Emergency Medicine.

Email: jaclyn.rychel@gmail.com

Ken Biermacher

Manager, Investor Relations

Ken Biermacher is a TIESRx™ Manager and currently manages Investor Relations. Ken is one of six founding members of the Texas-based business law firm Kane Russell Coleman & Logan PC, which has 95 attorneys based in offices in Dallas and Houston.

Though Ken’s principal practice area for the past 36 years has been complex business litigation, he has served as outside legal counsel to business enterprises, publicly traded and privately held, in countless areas of legal discipline and concerning many legal issues, including contracts, financial instruments, intellectual property, employment, business torts, securities, commercial real estate assets, manufacturing and transportation involved in federal and states courts and arbitration proceedings throughout the United States. He has also served as consulting counsel on many business contracts.

Trey Bayne

Manager, CFO

Trey Bayne is a TIESRx™ Manger and current acting Chief Financial Officer. He is Founder of the MB Group, LLC a certified public accounting and consulting firm and is the Principal In-Charge. As an entrepreneur, Trey appreciates the challenges of business and is committed to providing small to mid-market businesses, owners and stakeholders with essential tax and consulting expertise.

In 1996, Trey started his career servicing entrepreneurs in Ernst & Young LLP’s federal tax group. While with E&Y, Trey was involved in all aspects of tax compliance including; high-wealth individuals, real estate and oil and gas ventures, financial institutions, trust and estates, standard corporations and partnerships. After three years with Ernst & Young, Trey joined KPMG where he spent four years; one year in their federal tax group in Dallas as a Senior Consultant, followed by a three-year rotation in their international tax group in Paris, France as Manager. Trey’s international tax experience while with KPMG was intensive. He was located in KPMG’s Paris office, one of only four U.S. offices in Europe. Trey’s main responsibilities included consulting with European companies with U.S. operations, European companies acquiring another company with U.S. operations, pre and post-merger acquisition structure planning and heading the U.S. tax due diligence team in the Paris office.

Upon returning to the Dallas area in 2002, Trey joined a Top 25 DFW accounting firm as the Director of Taxation where he focused on servicing small and middle market businesses as well as individuals in all facets of tax matters.

During his many years in public accounting, Trey has performed all aspects of tax accounting including compliance, audit defense, entity formation, mergers and acquisitions, due diligence, state and local, and international tax consulting. With such a diverse background, Trey is comfortable working with all size companies from solopreneurs to Fortune 100 companies.

D. Bryan Jones

Manager, COO

Bryan Jones is a TIESRx™ Manager and advises the company on technical and product related initiatives. Bryan previously was a co-founder of b.well Health, a new company focused on solving the healthcare issues facing our country and constructed to fit the demands and needs of the 21st century. Prior to that, Bryan was the SVP Product and Solutions at Videology Group, the world’s leading Addressable Audience Platform, overseeing product development, product marketing and product solutions.

Bryan previously served as SVP, Innovation and Emerging Solutions for Videology, where he lead a team pioneering programmatic video across multiple screens, including linear TV, video on demand and mobile devices. Bryan joined Videology in 2012, following Videology’s acquisition of Collider Media, of which Bryan was founder, Chairman and CEO.

While leading Collider Media, Bryan developed the world’s first publisher-centric, data management platform for mobile and digital advertising, used by leading publishers around the world, and patented the core technology, linking offline data to mobile devices for purposes of delivering optimized content.

Prior to founding Collider, Bryan was the founder and CEO for Moximity, one of the pioneering companies focused on location-based social network with an emphasis on local content. Bryan began his career as a mergers-and-acquisitions and corporate finance attorney with DLA Piper, transacting over $3 billion in mergers and acquisitions, public offerings, venture investments and asset sales.

Strategic Advisory Board

Because we know that having influence from outside of the internal workings of a company is what helps it accelerate towards its goals, we have brought on advisors to help us shape our business more thoughtfully.

Sara Aswegan

With over 20 years in the pharma/biotech industry, Sara has extensive Global Rare Disease expertise spanning several therapeutic areas and functions (sales, training, marketing, management, alliances, business development, portfolio strategy, global leadership). She has a true passion for the rare disease space as evidenced by her success. Her accomplishments include:

  • Leadership of multiple global cross functional strategic teams and portfolios through the entire product lifecycle, creating value for all stakeholders
  • Identification and cultivation of key talent and succession planning
  • Comprehensive understanding of customer needs, industry, agency regulations she successfully led many multi-billion dollar portfolios
  • Extensive commercialization experience (ph 1 through post launch); including customer engagement (patient and caregiver) strategy
  • Drug pricing, value and market access strategy
  • Supply strategy and distribution management
  • Portfolio Optimization
  • Governance implementation and Operational Planning

She most recently served as Senior Vice President, Commercial, Global Strategy for Ultragenyx Pharmaceuticals, based in Basel, Switzerland (2016-Present). Prior to that, Sara held multiple roles with advancing responsibility with Shire focused on rare diseases (2007-2016), her most recent as Vice President, Product Strategy Lead, for both the GI and LSD-MPS Franchises based in the US and also Switzerland. Prior to joining Shire, Sara worked at Astellas, Sanofi and Bayer, all based in the US. Sara holds a B.A. from the University of Nebraska-Lincoln and Executive Education from Harvard School of Public Health and Colombia Business School.

Jean Campbell

Jean Campbell is nationally recognized as one of the leading rare disease patient advocates with an impressive record of success in development, patient advocacy and corporate relations. Serving nearly two decades with the National Organization for Rare Disorders (NORD) as Vice President of Development and then Vice President of Membership Development, Jean’s responsibilities included mentoring and consulting with many nonprofit organizations and their board of directors as well as establishing and maintaining relationships with the corporate sector. Under Jean’s leadership, there was significant expansion of several of NORD’s individual and organization membership programs along with the creation of NORD’s restricted research, disease specific regional meetings, NORD’s annual conference and Tribute Banquet, organization mentor and clinical broadcast programs. Jean also played a key role in the establishment of the NORD Corporate Council, which has grown to over 75 pharmaceutical and biotechnology companies.

A well-respected and widely-connected resource in the rare disease health community, Jean created her consulting firm, JF Campbell Consultants LLC, in 2010 to continue to work within the rare disease community, making vital connections that can positively impact this unique and often underserved population. 

Her expertise in patient advocacy, non-profit strategic planning, organizational governance, corporate relations, patient assistance programs and program management is extremely valuable to both the pharmaceutical and biotech industries as well as for the non-profit sector. Her depth of knowledge about rare diseases along with the challenges facing this community, make Jean’s expertise and experiences valuable resources for her current and potential clients.

Bruce Goldberg

Bruce Goldberg has enjoyed a 38-year career in numerous high-profile marketing positions. Currently he is CEO of the consultancy Goldberg Group (goldberggrp.com), which focuses on a range of marketing challenges including positioning, branding and naming for a range of firms including start-ups in Medical and Financial technology; consumer products; and sports management. He is also an active Venture Capital and Angel investor in healthcare; MedTech; and a Dallas-based craft brewer.

Previously, Bruce was Chief Marketing Officer for the International Securities Exchange (ISE), where he championed ISE’s brand from start-up to the world’s largest equity options exchange, a public offering as the first US electronic options exchange and buyout by Eurex/Deutsche Boerse. Bruce’s decade of leadership experience at ISE saw him involved in creating corporate and product brand campaigns from planning to execution; spearheading sales and business development, participating in diverse new product development initiatives; education; managing ISE’s corporate affairs function including media/public relations; their Washington DC government relations program comprising internal and external lobbying/chairing the PAC; and serving on numerous management steering committees.

Bruce’s work at ISE built on the exchange industry experience he acquired at the Chicago Board Options Exchange (CBOE), the world’s first and largest options exchange, where he was responsible for the creation and development of LEAPS® or Long-Term Equity AnticiPation Securities. LEAPS® represented a new way of trading, hedging, and investing that catered to the needs of a new audience for options, equity investors who were non-users of derivatives. Bruce’s innovative LEAPS® product expanded the user base during an industry contraction due to the 1987 and 1989 market events. He was also a founder of the OIC (Options Industry Council). He has also worked for Procter & Gamble; Frito-Lay, where he ran their two largest brands, Doritos and Lays; Pizza Hut and Brink’s Home Security. Bruce obtained his M.B.A from Cornell University and a B.S. from Union College.

Ciara Kennedy, Ph.D.

Ciara Kennedy was appointed Chief Operating Officer of Amplyx Pharmaceuticals in October 2015, following a successful Series B financing ($50M). Amplyx is developing novel treatments for life-threatening invasive fungal infections. Prior to this appointment, Ciara served as Chief Operating Officer at Lumena Pharmaceuticals, until the company was acquired by Shire Pharmaceuticals in June 2014 for ~$400M and as Vice President, Head of Cholestatic Liver Disease at Shire for 1-year post acquisition. As COO of Lumena, Ciara played a critical role in the development of assets licensed from Pfizer and Sanofi, raising $78M from venture capital to fund operations and preparing to take the company public. Ciara has a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotech industry. Prior to Lumena, Ciara held the positions of Vice President of Operations and Senior Director of Strategy and Corporate Development at Cypress Bioscience Inc. where she played a key role in the company’s FDA approval of Savella® for Fibromyalgia, corporate acquisitions and the in-licensing of several clinical assets. Prior to joining Cypress Bioscience, Ciara held several positions in the Program and Alliance department of Biogen Idec, managing multiple projects spanning the drug discovery and development continuum.

A Ph.D. scientist by training Ciara received her doctorate at the Queen’s University of Belfast, Northern Ireland. Following which she relocated to the Burnham Institute, La Jolla, California, to continue her research in the field of apoptotic proteases. In 2004 Ciara became a member of the inaugural class of the Rady School of Management at UCSD, and graduated with a Masters of Business Administration in 2006.

Michael Nissenbaum

Michael Nissenbaum joined Aprima Medical Software in 2004 after a highly successful career at Millbrook Corporation and GE Healthcare. As president of Millbrook Corporation, he oversaw five years of compounded revenue growth in excess of 80% and six product releases. During his tenure, the company grew from 24 employees to over 140 employees, supporting over 10,000 physicians in 65 specialties and sub-specialties, across the country.

At General Electric, Mike led the commercialization of GE Healthcare – Clinical Data Services, accelerating the growth of the medical record database from 11 practices delivering 600,000 records to 57 practices providing over 5.7 million records. This growth resulted in a fourfold increase in orders and a tripling of revenue.

Before Millbrook, Mike was associated with various technology companies in Texas and Illinois. He received an MBA from the University of Chicago and is a Certified Public Accountant and Chartered Financial Analyst®.

In The News

Recent press releases from TIESRx™.

Contact Us

Get in touch to find out more about the TIESRx™ platform.

 

Email Us